Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 14/20 | 0.49 |
| ▸ | PPARD | Q03181 | 14/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 13/20 | 0.45 |
| ▸ | PPARA | Q07869 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9850794 | 0.81 | L3MBTL1 (0.43) | PPARGPPARDFFAR1 | |
| SCHEMBL27094832 | 0.80 | HTT (0.37) | PPARGPPARDFFAR1 | |
| SCHEMBL27094571 | 0.80 | HTT (0.37) | PPARGPPARDFFAR1 | |
| SCHEMBL27094529 | 0.77 | AKR1B1 (0.39) | PPARGPPARDFFAR1 | |
| SCHEMBL203850 | 0.76 | PPARG (0.62) | PPARGPPARDFFAR1PPARA | |
| SCHEMBL204961 | 0.76 | PPARG (0.62) | PPARGPPARDFFAR1PPARA | |
| SCHEMBL28496840 | 0.75 | FFAR1 (0.44) | PPARGPPARDFFAR1PPARA | |
| SCHEMBL4040703 | 0.74 | MAOB (0.66) | PPARGPPARDFFAR1PPARAMAOB | |
| SCHEMBL19852041 | 0.72 | P2RX7 (0.39) | — | |
| SCHEMBL19839279 | 0.71 | PPARD (0.44) | PPARDFFAR1PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
| WO-2018026371-A1 | DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2018-02-08 | — | — | WO | disclosed |
| EP-0416740-A2 | Novel compounds with renin-inhibiting activity | Beecham Group p.l.c. (GB) | 1991-03-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SCN2A, HTR2A, HTR2C | PPARG 4228/4885PPARD 4644/4885FFAR1 3365/4885 |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SCN2A, HTR2A, HTR2C | PPARG 4228/4885PPARD 4644/4885FFAR1 3365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.